Study Status: Available
Recruit Status: Available
Study Type: Expanded Access
Official Title: An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS) and Downbeat The primary objective of the study is:
• To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available.
The secondary objective of the study is:
• To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus